Anti-Mouse VEGF Monoclonal Antibodies for Flow Cytometry

PA007517.m2a: Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: B20-4.1.1.1), Mouse IgG2a Kappa

Recombinant mouse IgG2a kappa monoclonal antibody. 
Clone: B20-4.1.1.1.
Isotype: Mouse IgG2a Kappa.
Source: The anti-mouse VEGF Monoclonal Antibody (Clone: B20-4.1.1.1) was produced in mammalian cells.
Conjugation: Non-conjugated.
Specificity/Sensitivity: The recombinant B20-4.1.1.1 antibody specifically binds to mouse VEGF.
Applications: Flow cytometry (FC), and Immunohistochemistry - Frozen (IHC-F).
Form of Antibody: 0.2 uM filtered solution, pH 7.4, containing 0.09% sodium azide.
Purity: >95% by SDS-PAGE under reducing conditions.

PA007517.h1Fs: Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: B20-4.1.1.1), Human IgG1 Fc Silent Kappa

Recombinant human IgG1 Monoclonal Antibody with Fc silent mutation. 
Clone: B20-4.1.1.1.
Isotype: Human IgG1 Fc Silent Kappa.
Source: The anti-mouse VEGF Monoclonal Antibody (Clone: B20-4.1.1.1) was produced in mammalian cells.
Conjugation: Non-conjugated.
Specificity/Sensitivity: The recombinant B20-4.1.1.1 antibody specifically binds to mouse VEGF.
Applications: Flow cytometry (FC), and Immunohistochemistry - Frozen (IHC-F).
Form of Antibody: 0.2 uM filtered solution, pH 7.4, containing 0.09% sodium azide.
Purity: >95% by SDS-PAGE under reducing conditions.

Shipping: The B20-4.1.1.1 antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, 2 to 8°C as supplied. Do not freeze it.

Related Recombinant IgG Reference Antibodies:
In vivo grade recombinant mouse IgG2a isotype control antibody

Syd Labs provides the following in vivo grade recombinant anti-mouse VEGF monoclonal antibodies:
In Vivo Grade Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: B20-4.1.1.1)
In Vivo Grade Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: G6-23)
In Vivo Grade Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: G6-31)

Syd Labs provides the following recombinant anti-mouse VEGF monoclonal antibodies for Flow Cytometry:
Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: B20-4.1.1.1) for Flow Cytometry
Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: G6-23) for Flow Cytometry
Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: G6-31) for Flow Cytometry

Syd Labs also provides the following anti-VEGF antibody biosimilar proteins:
Bevacizumab Biosimilar, research grade, anti-human VEGF monoclonal antibody
Bevacizumab Biosimilar, L234A L235A P329G (LALAPG) Fc silent mutant
Ramucirumab Biosimilar, research grade, anti-human VEGF / VEGFR2 / VEGFR-2 monoclonal antibody
Ranibizumab Biosimilar, research grade, anti-human VEGF monoclonal antibody
Brolucizumab Biosimilar, research grade, VEGF-A Monoclonal Antibody
Faricimab Biosimilar, research grade, Human ANGPT2/VEGFA Monoclonal Antibody

References of anti-mouse VEGF antibody for Flow Cytometry (Clone: B20-4.1.1.1):

An Anti-VEGF-B Antibody Reduces Abnormal Tumor Vasculature and Enhances the Effects of Chemotherapy
Kuo, C. Y., et al. Mol Cancer Ther. 2024 Aug 2;23(8):1069-1082. doi: 10.1158/1535-7163.MCT-23-0564. PMID: 38791979
(B) Top row: cell surface expression of VEGFR-1 (orange) and VEGFR-2 (green), was explored in four cancer cell lines (DU4475 MDA-MB-231, COLO205, and HT29) by antibody staining and flow cytometry analysis. Non-specific staining was not observed with the IgG2a isotype control murine antibody. Complementary actions of dopamine D2 receptor agonist and anti-vegf therapy on tumoral vessel normalization in a transgenic mouse model. Here we investigated the VEGFR1 ligand VEGF-B, which we demonstrate to be expressed in tumor cells and in tumor stroma and vasculature across a range of tumor types. We examined the anti-VEGF-B-specific monoclonal antibody 2H10 in preclinical xenograft models of breast and colorectal cancer, in comparison with the anti-VEGF-A antibody bevacizumab.
Tags: anti-mouse VEGF-B 2H10 antibody; anti-mouse VEGF-B 2H10 antibody for cancer research

Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody
Chen, C., et al. J Immunother Cancer. 2023 Apr;11(4):e006150. doi: 10.1136/jitc-2022-006150. PMID: 36990507
VEGF blockade using specific antibodies against VEGF or VEGFR2 increased HEVs in the TME and cytotoxic CD8(+) TILs, significantly improving the therapeutic efficacy of EAT strategies in preclinical models, supporting the clinical investigation of VEGF blockades to further enhance BsAb-based T cell immunotherapy. VEGF blockade enhances GD2-EAT infiltration into neuroblastoma and particularly, increased intratumoral CD8(+) T cells. (A) Neuroblastoma PDXs were treated with a combination of GD2-EATs and anti-VEGF (BVZ) or VEGFR2 antibody (DC101). Tumors were harvested on day 10 post-EAT treatment and analyzed by flow cytometry. BsAb-driven intratumoral T cell infiltration and in vivo antitumor response were evaluated using cancer cell line-derived xenografts (CDXs) or patient-derived xenografts (PDXs) carried out in BALB-Rag2 -/-IL-2R-γc-KO (BRG) mice. VEGF expression on human cancer cell lines was analyzed by flow cytometry, and VEGF levels in mouse serum were measured using VEGF Quantikine ELISA Kit.
Tags: anti-mouse VEGF (BVZ) antibody; anti-mouse VEGFR2 (DC101) antibody for cancer research

VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Hoefflin, K., et al. Oncoimmunology. 2015 Mar 4;4(5):e1008378. doi: 10.1080/2162402X.2014.1008378. PMID: 25601652
Each dot represents an individual mouse, histograms represent mean ± SEM of 2 pooled experiments with 3–5 mice/group. VEGF-A neutralization decreases expression of inhibitory receptors involved in exhaustion on CD8+ T cells in heterotopic and orthotopic mouse tumor models. Mice bearing subcutaneous CT26 tumors were treated with anti–VEGF-A antibody or mouse serum (as a control). Each dot represents an individual mouse, and histograms represent mean ± SEM of 2–4 pooled experiments with at least 4 mice/group. *, P = 0.0439; ***, P < 0.001. (e) Correlation of VEGF-A concentration/gram of tumor tissue and number of PD-1-expressing CD8+ T cells/gram of tumor tissue (determined by flow cytometry).
Tags: anti-mouse VEGF-A antibody for cancer research; anti-mouse VEGF-A antibody for flow cytometry

VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells
Chaurasiya, S., et al. Mol Ther. 2013 Jun;21(6):1014-23. doi: 10.1038/mt.2013.39. PMID: 23481323
Tumor-bearing animals were treated with either PBS (control) or oHSV by intratumoral injection and intraperitoneal IgG (control) or anti-VEGF antibodies r84 or bevacizumab. All treatments were given on day 0. Tumors were harvested on day +3 and analyzed for (a) tumor-derived hVEGF (n = 4–5), (b) host-derived mVEGF (n = 4–7), (c) CD11b+ cells by flow cytometry (n = 4) including neutrophils (CD11b+Gr1+F4/80−), myeloid-derived suppressor cells (CD11b+Gr1−F4/80−), and macrophages (CD11b+Gr1−F4/80+). Anti-VEGF antibodies, bevacizumab and r84, the latter of which binds VEGF and selectively inhibits binding to VEGF receptor-2 (VEGFR2) but not VEGFR1, enhanced the antitumor effects of virotherapy, in part due to decreased angiogenesis but not increased virus production.
Tags: anti-mouse VEGF (r84) antibody; anti-mouse VEGF (bevacizumab) antibody for cancer research

Immunization with synthetic VEGF peptides in ovarian cancer
Shah, M., et al. Gynecol Oncol. 2010 Nov;119(2):224-8. doi: 10.1016/j.ygyno.2010.06.321. PMID: 20822802
Resolution of mouse VEGF was seen in lanes immunoprecipitated with rabbit VEGF peptide antibodies with the appropriate positive (anti-mouse VEGF antibody right lane) and negative (normal IgG, left lane) controls. VEGF peptide antibodies recognize and bind VEGF, leading to a decrease in the interaction between the VEGF ligand and its receptors. Flow cytometry demonstrating a shift in population when rhVEGF-stimulated human umbilical vein endothelial cells (HUVEC) are pre-incubated with monoclonal anti-VEGF antibodies, anti-MVF-VEGF (102-122) antibodies, and anti-MVF-VEGF(127-144) antibodies. Active immunization with VEGF peptides elicits antibodies that inhibit tumor growth by blocking VEGF-dependent angiogenesis.
Tags: anti-mouse VEGF antibody for mouse tumor model; anti-mouse VEGF monoclonal antibody

For more references about anti-mouse VEGF antibody for Flow Cytometry (Clone: B20-4.1.1.1), please contact our scientific support team with message@sydlabs.com.